Divide and Conquer
Divide and Conquer is a Cambridge, US-based private biotechnology company founded in 2018 that is developing a new class of oncology therapeutics. It is backed by healthcare-focused investor Medicxi and operates with a small early-stage team.
- Company typePrivate
- Founded2018
- HeadquartersCambridge, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Divide and Conquer does
Divide and Conquer is a private, early-stage biotechnology company headquartered in Cambridge, United States, founded in 2018. The company is focused on the discovery and development of a new class of oncology therapeutics. With a stated headcount of 1-10 employees, the firm operates at a small scale consistent with preclinical or discovery-stage biotech operations, and its public web presence (conquer.bio) currently shows only a default cPanel parked page, indicating minimal commercial-facing footprint.
The company has attracted institutional capital from Medicxi, a healthcare-dedicated investment firm, securing a $12,433,002 financing round dated September 23, 2019. This funding round, classified in the available records as the company's Round 2, represents the principal disclosed capital event and indicates progression through early biotech financing stages. David Grainger is identified in available records as a Director, providing governance oversight.
The underlying therapeutic platform, specific molecular targets, pipeline composition, business model mechanics, pricing structure, partnerships relevant to the oncology thesis, and customer or commercialization profile are not disclosed in the available source material. This degree of information scarcity is typical of stealth-mode or pre-clinical biotech entities, and it materially limits the visibility of near-term milestones and revenue trajectories. Note that some source records associate the company name "Divide and Conquer" / "Divide/Conquer" with a film-production entity (e.g., partnerships with Legendary Entertainment and Angry Films Entertainment on the Faces of Death remake); the relevance of those data to the biotech thesis is unclear from the source material and is flagged for diligence.
Divide and Conquer firmographics
Firmographics- Name
- Divide and Conquer
- Website
- https://conquer.bio
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Divide and Conquer is a Cambridge, US-based private biotechnology company founded in 2018 that is developing a new class of oncology therapeutics. It is backed by healthcare-focused investor Medicxi and operates with a small early-stage team.
- Ownership category
- akta.pro rank
Divide and Conquer industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where Divide and Conquer is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Divide and Conquer business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Divide and Conquer product offering
Product offeringCore offering
Divide and Conquer (also styled as Divide/Conquer) is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company operates with a small team of 1-10 employees focused on the discovery and development of a new class of oncology therapeutics. Its work centers on early-stage cancer drug discovery and biological research to address unmet needs in oncology treatment.
Differentiator
Problem solved
Functional benefit
Companies that use Divide and Conquer
Customer profileIdeal customer profiles1 record
Divide and Conquer technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Divide and Conquer partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Legendary EntertainmentcoreLegendary Entertainment is a co-producer on the Faces of Death remake. The production involves Legendary Entertainment, Angry Films Entertainment, and Divide/Conquer, with the project having been in development for 16 years before reaching production. The film is set for release on April 10.
- Angry Films EntertainmentcoreAngry Films Entertainment is a co-producer on the Faces of Death remake alongside Legendary Entertainment and Divide/Conquer. The project has been in development for 16 years.
Recent moves3 records
Expansion highlights3 records
Divide and Conquer competitors and assessment
Company assessmentDirect peers
- Bicycle Therapeutics: Cambridge, UK-based clinical-stage biotech developing bicyclic peptides for oncology. Directly comparable geography, stage, and therapeutic focus, and a typical reference point for differentiated-mechanism oncology biotechs emerging from the Cambridge cluster.
- Crescendo Biologics: Cambridge, UK-based developer of T-cell engagers and immune-oncology biologics. Comparable in size, stage, and oncology focus, and another example of a Cambridge-anchored biotech pursuing a defined class of cancer therapeutics.
- CellCentric: UK-based oncology biotech (also previously backed by Medicxi) developing small-molecule cancer therapeutics. Highly comparable given shared VC backing and oncology focus, and illustrates the typical trajectory and challenges for Medicxi oncology assets.
- Achilles Therapeutics: London-based clinical-stage biotech developing personalised neoantigen cancer immunotherapies. Similar UK-base, oncology focus, and emerging-stage profile, providing a useful stage-comparable for forward planning.
- F-star Therapeutics: Cambridge-area biotech developing tetravalent bispecific antibodies for oncology and immunology. Comparable geography, modality innovation angle, and oncology focus, and illustrates the path from discovery biotech to clinical/partnered asset.
Broad incumbents
- Adaptimmune: Oxfordshire-headquartered clinical-stage biotech developing engineered TCR therapies for solid tumours. Same UK oncology orientation but at meaningfully larger scale and public-company status, serving as a broader-incumbent reference point.
- Autolus Therapeutics: London-headquartered clinical-stage biotech developing programmed CAR-T cell therapies for cancer. Same UK oncology innovation ecosystem, listed on Nasdaq, and provides a useful scale reference for what a successful UK oncology biotech trajectory looks like.
- AstraZeneca: Global biopharma headquartered in Cambridge, UK with one of the world's largest oncology pipelines. Functions as a broad-incumbent reference point and a likely potential acquirer or partner for any Cambridge oncology biotech with a differentiated mechanism.
Emerging players
- Vaccitech: Oxford-based immunology and oncology biotech, also backed by Medicxi. Shares the Medicxi oncology/immunology platform and UK-base with Divide and Conquer, making it a relevant emerging-player peer for understanding capital and pipeline expectations.
Regional players
- eTheRNA immunotherapies: Belgium-based clinical-stage biotech developing mRNA-based immunotherapies for cancer. Operates in a closely related modality space (cancer immunotherapy) but is regional (continental Europe) rather than directly UK-based, making it a useful regional peer.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Divide and Conquer social profiles
Digital presenceDivide and Conquer financial estimates
Financial estimateRevenue estimate
Valuation estimate
Divide and Conquer leadership team
Management profileNumber of profiles
Profiles1 record
Divide and Conquer funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Divide and Conquer M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Divide and Conquer
What does Divide and Conquer do?
Divide and Conquer (also styled as Divide/Conquer) is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. The company operates with a small team of 1-10 employees focused on the discovery and development of a new class of oncology therapeutics. Its work centers on early-stage cancer drug discovery and biological research to address unmet needs in oncology treatment.
Is Divide and Conquer a public or private company?
Divide and Conquer is a private company. It is classified as venture growth investor backed and is currently operating.
When was Divide and Conquer founded?
Divide and Conquer was founded in 2018. It employs 1 to 10 people.
Where is Divide and Conquer based?
Divide and Conquer is headquartered in Cambridge, United States, in the North America region.
Who are Divide and Conquer's main competitors?
Direct peers on record are Bicycle Therapeutics, Crescendo Biologics, CellCentric, Achilles Therapeutics and F-star Therapeutics. Broad incumbents are Adaptimmune, Autolus Therapeutics and AstraZeneca. Vaccitech is listed as an emerging player. eTheRNA immunotherapies is listed as a regional player.
Does Divide and Conquer have an API?
No public API is recorded for Divide and Conquer.
What industry is Divide and Conquer in?
Divide and Conquer's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.